Investor Presentaiton
Total Revenues
Quarterly trend snapshot
Covid Revenues
Non-Covid Revenue
251.0
+7%
268.0
264.2
259.8
243.7
Q4FY21
Q1FY22
Q2FY22
Covid Revenue Contribution
Q3FY22
Q4FY22
19%
17%
14%
14%
62.5
49.4
40.8
42.8
12%
38.0
Q4FY21
Q1FY22
Q2FY22
Q3FY22
Q4FY22
+5%
326.8
291.7
302.6
293.1
305.9
Q4FY21
Q1FY22
Q2FY22
Q3FY22
Q4FY22
Including Hitech Diagnostics from 22nd Oct, 2021
METROPOLIS
The Pathology Specialist
Key Highlights
ā Q4FY22 witnessed a disruption in business
on account of omicron variant in the month of
January 2022
ā Non-Covid business was impacted due to
omicron disruption; Inpsite of the disruption
Non-covid revenue grew by 7% on YoY basis
in Q4FY22
Covid RT-PCR revenue was impacted on
account of shift to self testing at home during
omicron wave in addition to lower pricing by
Government on covid tests
6View entire presentation